Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene

Jun Akanuma, Kaoru Wataya, Yoichi Matsubara, Shigeo Kure, Kuniaki Narisawa, Franco Tarqni, Ichiro Yoshida, Makoto Yoshino, Junichi Kira, Teiji Yamamoto

Research output: Contribution to journalArticle

Abstract

Carnitine palmitoyltransferase II (CPTII) deficiency manifests as various clinical phenotypes: a relatively mild form with muscular symptoms and a severe phenotype presenting with hepatocardiomuscular manifestations. We have investigated three Japanese patients with CPT II deficiency. Molecular analysis revealed two novel missense mutations, a glutamate (174)-to-lyine substitution (E174K) and a phenylalanine (383)-to-tyrosine substitution (F383Y) in the CPTII cDNA. Transfection experiments demonstrated that the two mutations reduced CPTII catalytic activity. Case 1 (muscular form) was homozygous for the E174K mutation, whereas case 2 (hepatic form) was homozygous for the F383Y mutation. Interestingly, case 3, who was a compound hétérozygote for E174K and F383Y, exhibited hepatic symptoms. We also identified a polymorphism in the CPTII gene, a phenylalanine (352)-to-cysteine substitution (F352C). According to an expression analysis, this mutation did not alter CPTII activity. It was present in 21 out of 100 normal alleles in the Japanese population, but was not observed among Caucasians. Genotyping with this polymorphism and the p/eviously reported polymorphisms V368I and M647V allowed normal alleles to be classified into five naplotypes. In all three families, the E174K mutation resided only on F1V1M1 allele, while the F383Y mutation was observed on F2V2M1 allele, suggesting a single origin of each mutation.

Original languageEnglish
Number of pages1
JournalJapanese Journal of Human Genetics
Volume42
Issue number1
Publication statusPublished - Dec 1 1997
Externally publishedYes

Fingerprint

Carnitine O-Palmitoyltransferase
Mutation
Genes
Alleles
Phenylalanine
Phenotype
Liver
Missense Mutation
Transfection
Cysteine
Tyrosine
Glutamic Acid
Complementary DNA

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)

Cite this

Akanuma, J., Wataya, K., Matsubara, Y., Kure, S., Narisawa, K., Tarqni, F., ... Yamamoto, T. (1997). Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene. Japanese Journal of Human Genetics, 42(1).

Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene. / Akanuma, Jun; Wataya, Kaoru; Matsubara, Yoichi; Kure, Shigeo; Narisawa, Kuniaki; Tarqni, Franco; Yoshida, Ichiro; Yoshino, Makoto; Kira, Junichi; Yamamoto, Teiji.

In: Japanese Journal of Human Genetics, Vol. 42, No. 1, 01.12.1997.

Research output: Contribution to journalArticle

Akanuma, J, Wataya, K, Matsubara, Y, Kure, S, Narisawa, K, Tarqni, F, Yoshida, I, Yoshino, M, Kira, J & Yamamoto, T 1997, 'Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene', Japanese Journal of Human Genetics, vol. 42, no. 1.
Akanuma J, Wataya K, Matsubara Y, Kure S, Narisawa K, Tarqni F et al. Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene. Japanese Journal of Human Genetics. 1997 Dec 1;42(1).
Akanuma, Jun ; Wataya, Kaoru ; Matsubara, Yoichi ; Kure, Shigeo ; Narisawa, Kuniaki ; Tarqni, Franco ; Yoshida, Ichiro ; Yoshino, Makoto ; Kira, Junichi ; Yamamoto, Teiji. / Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene. In: Japanese Journal of Human Genetics. 1997 ; Vol. 42, No. 1.
@article{83963c132df446b49f36e6259a539381,
title = "Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene",
abstract = "Carnitine palmitoyltransferase II (CPTII) deficiency manifests as various clinical phenotypes: a relatively mild form with muscular symptoms and a severe phenotype presenting with hepatocardiomuscular manifestations. We have investigated three Japanese patients with CPT II deficiency. Molecular analysis revealed two novel missense mutations, a glutamate (174)-to-lyine substitution (E174K) and a phenylalanine (383)-to-tyrosine substitution (F383Y) in the CPTII cDNA. Transfection experiments demonstrated that the two mutations reduced CPTII catalytic activity. Case 1 (muscular form) was homozygous for the E174K mutation, whereas case 2 (hepatic form) was homozygous for the F383Y mutation. Interestingly, case 3, who was a compound h{\'e}t{\'e}rozygote for E174K and F383Y, exhibited hepatic symptoms. We also identified a polymorphism in the CPTII gene, a phenylalanine (352)-to-cysteine substitution (F352C). According to an expression analysis, this mutation did not alter CPTII activity. It was present in 21 out of 100 normal alleles in the Japanese population, but was not observed among Caucasians. Genotyping with this polymorphism and the p/eviously reported polymorphisms V368I and M647V allowed normal alleles to be classified into five naplotypes. In all three families, the E174K mutation resided only on F1V1M1 allele, while the F383Y mutation was observed on F2V2M1 allele, suggesting a single origin of each mutation.",
author = "Jun Akanuma and Kaoru Wataya and Yoichi Matsubara and Shigeo Kure and Kuniaki Narisawa and Franco Tarqni and Ichiro Yoshida and Makoto Yoshino and Junichi Kira and Teiji Yamamoto",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "42",
journal = "Journal of Human Genetics",
issn = "1434-5161",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Identification of mis sense mutations and haplotyping of carnitine palmitoyltransferase II gene

AU - Akanuma, Jun

AU - Wataya, Kaoru

AU - Matsubara, Yoichi

AU - Kure, Shigeo

AU - Narisawa, Kuniaki

AU - Tarqni, Franco

AU - Yoshida, Ichiro

AU - Yoshino, Makoto

AU - Kira, Junichi

AU - Yamamoto, Teiji

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Carnitine palmitoyltransferase II (CPTII) deficiency manifests as various clinical phenotypes: a relatively mild form with muscular symptoms and a severe phenotype presenting with hepatocardiomuscular manifestations. We have investigated three Japanese patients with CPT II deficiency. Molecular analysis revealed two novel missense mutations, a glutamate (174)-to-lyine substitution (E174K) and a phenylalanine (383)-to-tyrosine substitution (F383Y) in the CPTII cDNA. Transfection experiments demonstrated that the two mutations reduced CPTII catalytic activity. Case 1 (muscular form) was homozygous for the E174K mutation, whereas case 2 (hepatic form) was homozygous for the F383Y mutation. Interestingly, case 3, who was a compound hétérozygote for E174K and F383Y, exhibited hepatic symptoms. We also identified a polymorphism in the CPTII gene, a phenylalanine (352)-to-cysteine substitution (F352C). According to an expression analysis, this mutation did not alter CPTII activity. It was present in 21 out of 100 normal alleles in the Japanese population, but was not observed among Caucasians. Genotyping with this polymorphism and the p/eviously reported polymorphisms V368I and M647V allowed normal alleles to be classified into five naplotypes. In all three families, the E174K mutation resided only on F1V1M1 allele, while the F383Y mutation was observed on F2V2M1 allele, suggesting a single origin of each mutation.

AB - Carnitine palmitoyltransferase II (CPTII) deficiency manifests as various clinical phenotypes: a relatively mild form with muscular symptoms and a severe phenotype presenting with hepatocardiomuscular manifestations. We have investigated three Japanese patients with CPT II deficiency. Molecular analysis revealed two novel missense mutations, a glutamate (174)-to-lyine substitution (E174K) and a phenylalanine (383)-to-tyrosine substitution (F383Y) in the CPTII cDNA. Transfection experiments demonstrated that the two mutations reduced CPTII catalytic activity. Case 1 (muscular form) was homozygous for the E174K mutation, whereas case 2 (hepatic form) was homozygous for the F383Y mutation. Interestingly, case 3, who was a compound hétérozygote for E174K and F383Y, exhibited hepatic symptoms. We also identified a polymorphism in the CPTII gene, a phenylalanine (352)-to-cysteine substitution (F352C). According to an expression analysis, this mutation did not alter CPTII activity. It was present in 21 out of 100 normal alleles in the Japanese population, but was not observed among Caucasians. Genotyping with this polymorphism and the p/eviously reported polymorphisms V368I and M647V allowed normal alleles to be classified into five naplotypes. In all three families, the E174K mutation resided only on F1V1M1 allele, while the F383Y mutation was observed on F2V2M1 allele, suggesting a single origin of each mutation.

UR - http://www.scopus.com/inward/record.url?scp=33748142132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748142132&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748142132

VL - 42

JO - Journal of Human Genetics

JF - Journal of Human Genetics

SN - 1434-5161

IS - 1

ER -